Prestige BioPharma Limited
Prestige BioPharma Limited, a biopharmaceutical company, engages in the research and development and marketing of biosimilars, antibody drugs, and vaccines in Singapore. The company offers Trastuzumab biosimilar for the treatment of breast cancer; Bevacizumab biosimilar for the treatment in oncology; and PBP1502, an adalimumab biosimilar, which is in Phase 1 clinical trial for the treatment in im… Read more
Prestige BioPharma Limited (950210) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.026x
Based on the latest financial reports, Prestige BioPharma Limited (950210) has a cash flow conversion efficiency ratio of -0.026x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-13.13 Billion) by net assets (₩499.31 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Prestige BioPharma Limited - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Prestige BioPharma Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Prestige BioPharma Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Prestige BioPharma Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
I&C Technology Co. Ltd
KQ:052860
|
0.261x |
|
West Vault Mining Inc
OTCQX:WVMDF
|
-0.005x |
|
Spyrosoft S.A.
WAR:SPR
|
0.126x |
|
HMA AGRO INDUSTRIES ORD (BSE)
NSE:HMAAGRO
|
0.023x |
|
VRX Silica Ltd
AU:VRX
|
-0.066x |
|
Ausquest Ltd
AU:AQD
|
-0.030x |
|
Red Pine Exploration Inc
OTCQB:RDEXF
|
-0.383x |
|
BAHADIR KIMYA
IS:BAHKM
|
N/A |
Annual Cash Flow Conversion Efficiency for Prestige BioPharma Limited (2018–2025)
The table below shows the annual cash flow conversion efficiency of Prestige BioPharma Limited from 2018 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | ₩505.76 Billion | ₩-54.34 Billion | -0.107x | -15.32% |
| 2024-06-30 | ₩515.50 Billion | ₩-48.03 Billion | -0.093x | +15.57% |
| 2023-06-30 | ₩546.23 Billion | ₩-60.27 Billion | -0.110x | -3.34% |
| 2022-06-30 | ₩429.94 Billion | ₩-45.91 Billion | -0.107x | -297.46% |
| 2021-06-30 | ₩574.96 Billion | ₩-15.45 Billion | -0.027x | +70.20% |
| 2020-06-30 | ₩137.80 Billion | ₩-12.42 Billion | -0.090x | -238.93% |
| 2019-06-30 | ₩58.19 Billion | ₩3.78 Billion | 0.065x | +197.35% |
| 2018-06-30 | ₩27.99 Billion | ₩-1.87 Billion | -0.067x | -- |